P-PSMA-101 CAR-T Cells for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Poseida Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.

Eligibility Criteria

This trial is for adults over 18 with advanced prostate cancer (mCRPC) or salivary gland cancers (SGC). Participants should be relatively healthy, able to perform daily activities with ease or minor difficulty (ECOG status of 0-1), and have organs functioning within certain limits. Men must agree to use birth control during the study and for two years after.

Inclusion Criteria

I am 18 years old or older.

My cancer can be measured by scans or, if only in bones, by a PSA test showing at least 1 ng/mL.

I can carry out all my usual activities without help.

See 4 more

Treatment Details

Interventions

P-PSMA-101 CAR-T cells (CAR T-cell Therapy)
Rimiducid (Other)

Trial OverviewThe trial is testing P-PSMA-101 CAR-T cells, a type of personalized immune cell therapy designed to target cancer cells in patients with mCRPC and SGC. It's an open-label study where everyone gets the treatment, and doses will increase gradually to find out how much can be given safely.

Participant Groups

4Treatment groups

Experimental Treatment

Group I: P-PSMA-101 CAR-T cells (Single Dose - Part 1c)Experimental Treatment2 Interventions

Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.

Group II: P-PSMA-101 CAR-T cells (Single Dose - Part 1a)Experimental Treatment2 Interventions

Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.

Group III: P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)Experimental Treatment2 Interventions

Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.

Group IV: P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)Experimental Treatment2 Interventions

Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.